NCT01191086

Open-label Extension Study to Evaluate the Safety of USL255 in Patients With Refractory Partial-onset Seizures

Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients With Refractory Partial-Onset Seizures Who Had Participated in P09-004, a Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 210 (actual)
• Sponsor: Upsher-Smith Laboratories · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to examine the safety of USL255 as adjunctive therapy in patients with refractory partial onset-seizures.

Conditions

• Epilepsy

Interventions

Type	Name	Description
DRUG	USL255

Timeline

• Start date: 2010-10-01
• Primary completion: 2014-05-01
• Completion: 2014-05-01
• First posted: 2010-08-30
• Last updated: 2015-02-23
• Results posted: 2015-02-23

Locations

68 sites across 15 countries: United States, Argentina, Australia, Belgium, Canada, Chile, Germany, Greece, India, Israel, New Zealand, Poland, Russia, South Africa, Spain